Please check your internet connection and try again.
# Walethmade bromide
*Note: Please confirm the spelling of this agent. "Walethmade bromide" does not correspond to a recognized pharmaceutical entity in clinical databases. It is possible this refers to **Aclidinium bromide** or **Umeclidinium bromide** (LAMA agents). Please verify the agent name before clinical application.*
## Overview
Assuming an anticholinergic/muscarinic antagonist classification (e.g., LAMA), these agents function as long-acting muscarinic antagonists that produce bronchodilation by inhibiting M3 receptors on airway smooth muscle.
## Primary Indications
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
## Adult Dosing
* **Aclidinium bromide:** 400 mcg via dry powder inhaler (DPI) twice daily.
* **Umeclidinium bromide:** 62.5 mcg via dry powder inhaler once daily.
* *Note: Dosing depends on specific device and local formulary protocols.*
## Pediatric Dosing
* **Not established.** These agents are not indicated for pediatric patients or the treatment of asthma.
## Dose Adjustments
* **Renal/Hepatic Impairment:** Generally no dose adjustment required, but caution is advised in severe hepatic or renal impairment due to theoretical increase in drug exposure.
## Contraindications
* Hypersensitivity to the drug or its components (e.g., milk proteins in some DPI formulations).
* Acute treatment of bronchospasm (not for rescue).
* Narrow-angle glaucoma (use with caution).
* Urinary retention (use with caution in patients with prostatic hyperplasia or bladder-neck obstruction).
## Adverse Effects
* **Common:** Nasopharyngitis, headache, cough, upper respiratory tract infection.
* **Serious:** Paradoxical bronchospasm, urinary retention, worsening of narrow-angle glaucoma, and anticholinergic systemic effects (dry mouth, blurred vision, constipation).
## Key Drug Interactions
* **Anticholinergics:** Concomitant use with other anticholinergic-containing drugs may increase the risk of adverse effects. Exercise caution with Ipratropium or Tiotropium.
## Monitoring
* Monitor for paradoxical bronchospasm upon administration.
* Assess for new-onset urinary retention or eye pain/blurred vision (signs of glaucoma).
* Evaluate COPD symptom control and frequency of rescue inhaler use.
## Clinical Pearls
* **Rescue Use:** Not for acute deterioration of COPD. Patients must have a separate short-acting beta-agonist (SABA) for rescue use.
* **Technique:** Proper inhalation technique is critical for DPI efficacy. Ensure the patient exhales away from the device before inhaling.
* **Systemic Effects:** While these agents are designed for local lung deposition, systemic absorption can occur; monitor patients with pre-existing urinary or ocular conditions closely.
***
**Educational Disclaimer:** This information is for educational purposes only. Please verify current prescribing information, local hospital protocols, and contraindications via official resources (e.g., FDA-approved package inserts or Lexicomp) before clinical use. Please re-verify the name of the drug.
